Labcyte Commends Institute for Molecular Medicine Finland – Pfizer Leukemia Study Results
13 Feb 2015
Labcyte, a company revolutionizing life science research with its patented acoustic liquid handling technology, has praised the results of an international collaboration between the Institute for Molecular Medicine Finland (FIMM), University of Helsinki and the pharmaceutical company Pfizer. The research, described on 9 February, 2015, in the journal Nature[1], identified a previously unrecognized action of Pfizer’s axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia.
“This marks yet another major accomplishment for FIMM and an important step towards improved care for patients with leukemia,” says Mark Fischer-Colbrie, CEO and president of Labcyte. “FIMM’s innovative approach to characterizing drug resistance and the implications for personalized treatment is inspirational to many in our industry.” Labcyte works with FIMM to develop applications for its acoustic liquid handling technology.
In a groundbreaking Cancer Discovery publication in September 2013[2] researchers from FIMM described an Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. This novel iterative approach was developed to improve the predictability of drug response in cancer cells allowing FIMM researchers to adjust cancer treatment for each patient individually. A key component of ISM is the use of Drug Sensitivity and Resistance Testing (DSRT) to assess the effects of repurposed therapeutics for cancer treatment. The identification of a new action for axitinib, a drug originally developed by Pfizer to treat advanced renal cancer, highlights the power of the approach to improve patient care.
FIMM’s ISM strategy leverages the unique capabilities of Labcyte’s Echo® liquid handler and Access™ Workstation. During a multi-year collaboration Labcyte and FIMM determined that the ability to transfer liquids in increments of billionths of a liter with precision and accuracy is essential for achieving the high quality of data and dramatic cost reductions required to make the program successful.
“FIMM is dedicated to explore individualized system medicine in cancer treatment,” said Professor Olli Kallioniemi, the director of FIMM. “Direct testing of patient cells with approved cancer treatments allow us to hone in on tailored therapeutic options. We are able to observe a variety of therapies that might be re-purposed for treating cancer as well as to identify potential pathways for future drug development. Labcyte’s innovative products allow us to develop and scale our programs with great efficiency.”
1 Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Tea Pemovska, Eric Johnson, Mika Kontro, Gretchen A. Repasky, Jeffrey Chen, Peter Wells, Ciarán N. Cronin, Michele McTigue, Olli Kallioniemi, Kimmo Porkka, Brion W. Murray & Krister Wennerberg. 2015. Nature.
Advance online publication: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14119.html
2 Tea Pemovska, Mika Kontro, Bhagwan Yadav, et al., “Individualized Systems Medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia,” Cancer Discovery, 2013, 3:1416-1429.
Related Products
Request Quote for All Products
Access™ Laboratory Workstation
Small-Scale Automation with Large-Scale Results Access™ laboratory workstations multiply the benefits of the Echo® liquid handler by improving overall assay throughput and reproducibility. With the ability to integrate a variety of devices and the modularity to scale when needed, each workstation offers the flexibility required by frequently-changing assay requirements. All Access workstations are optimized at install and include all safety mechanisms required for CE compliance. Access workstations use Labcyte Tempo™ automation control software to manage the system configuration and schedule automated routines. Protocols created from Echo® software applications can be imported into Tempo™ software and quickly converted into fully automated routines. Support for a Range of Applications Assay ready plate preparation Lead optimization and secondary screening assays High-throughput gene expression assays Automated protein crystallography setup
Echo® 500 Series Liquid Handlers
The Echo® liquid handler revolutionizes liquid handling with acoustic energy. Sound waves eject precisely sized droplets from a source onto a microplate, slide or other surface suspended above the source. This product does not use tips, pin tools or nozzles—completely eliminating contact between the instrument and the liquid. The Echo liquid handler provides powerful benefits: Tipless transfer, resulting in dramatic cost savings Improved information about sample integrity and improved transfer quality through measurement of DMSO hydration level Elimination of the need for calibration through Dynamic Fluid Analysis™ technology, a patented Labcyte process Elimination of cross-contamination, carryover or leachates through non-contact transfer Accurate, precise movement of nanoliter-scale quantities, enabling assay miniaturization and further reducing costs Better results through direct dilution of compounds, an improvement over serial dilution methods Greatly simplified assay development and dilution processes through the flexibility to transfer any volume of liquid from any well to any other well